Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)

(November 15, 2017)

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- “Cutaneous T-cell lymphoma is a blood cancer... Continue Reading


FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma

(November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading


Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer

(October 23, 2017)

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 with Keytruda® (pembrolizumab) is superior... Continue Reading


FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma

(October 18, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading


FDA Approves Aliqopa for Relapsed Follicular Lymphoma

(October 4, 2017)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma... Continue Reading


Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

(September 11, 2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced... Continue Reading


Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma

(August 9, 2017)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent... Continue Reading


Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers

(August 2, 2017)

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric... Continue Reading


Chimeric Antigen Receptor (CAR) T-cell Immunotherapy – Crafting a Better T Cell for Immunotherapy

(July 25, 2017)

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult B-cell Acute Lymphoblastic Leukemia.  CAR-T also shows promise in ALL, CLL, other B-cell malignancies, and other... Continue Reading


Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

(July 12, 2017)

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become... Continue Reading


Latest Non-Hodgkin\'s Lymphoma News By Stage


Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

CAR Therapy Effective in Advanced Lymphoma

(June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading


HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

(December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading


Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL

(September 4, 2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading


Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI)

(September 3, 2014)

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced... Continue Reading


Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients

(May 28, 2014)

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy... Continue Reading


More Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

Follicular Lymphoma

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma

(October 18, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading


Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma

(January 5, 2017)

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan® (rituximab) plus chemotherapy, and should now be... Continue Reading


Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma

(December 15, 2016)

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were... Continue Reading


Opdivo® Highly Effective for Some Patients with Lymphomas

(August 16, 2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal... Continue Reading


CAR Therapy Effective in Advanced Lymphoma

(June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading


More Follicular Lymphoma

Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

CAR Therapy Effective in Advanced Lymphoma

(June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading


HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

(December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading


Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL

(September 4, 2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading


Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI)

(September 3, 2014)

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced... Continue Reading


Treatment with Early Stem Cell Transplant Improves Outcomes in Aggressive NHL

(November 12, 2013)

Early autologous stem cell transplantation resulted in improved progression-free survival in patients with high-intermediate risk or high-risk disease who experienced a response to induction therapy, according to the results of a study published in the... Continue Reading


More Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

Indolent/Low Grade Non-Hodgkin's Lymphoma

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia

(February 24, 2015)

The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma. Imbruvica® is the first therapy indicated specifically for Waldenström’s... Continue Reading


HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

(December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading


Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment

(July 21, 2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood... Continue Reading


Celiac Disease Associated with Higher Risk of Lymphoma

(September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading


Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma

(February 8, 2013)

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of... Continue Reading


More Indolent/Low Grade Non-Hodgkin's Lymphoma

Mantle Cell Non-Hodgkin's Lymphoma

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma

(November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading


Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma

(August 9, 2017)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent... Continue Reading


CAR Therapy Effective in Advanced Lymphoma

(June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading


HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

(December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading


Imbruvica Approved for Mantle Cell Lymphoma

(January 23, 2014)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica™ (ibrutinib) for the treatment of patients with mantle cell lymphoma, a rare and aggressive type of blood cancer. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the... Continue Reading


More Mantle Cell Non-Hodgkin's Lymphoma

Recurrent Non-Hodgkin's Lymphoma

CAR Therapy Effective in Advanced Lymphoma

(June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading


HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

(December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading


Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL

(September 4, 2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading


Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI)

(September 3, 2014)

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced... Continue Reading


Celiac Disease Associated with Higher Risk of Lymphoma

(September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading


More Recurrent Non-Hodgkin's Lymphoma

Screening/Prevention Non-Hodgkin's Lymphoma

Link Between Allergies and Blood Cancers in Women

(January 1, 2014)

Researchers hare found a link between airborne allergies and the risk of blood cancers in women, according to the results of a study published in the American Journal of Hematology. Cancer research has increasingly become focused on the immune system... Continue Reading


Celiac Disease Associated with Higher Risk of Lymphoma

(September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading


Aspirin Continues to Look Promising for Cancer Prevention

(March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading


Organ Transplant Recipients Have Increased Cancer Risk

(November 9, 2011)

People who have received a solid organ transplant (such as a kidney or liver) are twice as likely as people in the general population to develop cancer. These results were published in the Journal of the American Medical Association. In 2010, more than... Continue Reading


Greater Cancer Risk Among Taller Women

(July 28, 2011)

Taller women may have an increased risk of developing certain cancers. Overall, cancer risk increases by 16% for every 4-inch increase in height. These findings were recently reported in Lancet Oncology. Greater insight into height and cancer risk may... Continue Reading


More Screening/Prevention Non-Hodgkin's Lymphoma

T-Cell Non-Hodgkin's Lymphoma

Opdivo® Highly Effective for Some Patients with Lymphomas

(August 16, 2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal... Continue Reading


CAR Therapy Effective in Advanced Lymphoma

(June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading


FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma

(January 19, 2015)

The U. S. Food and Drug Administration has granted Fast Track designation the synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation from the FDA is reserved for drugs that demonstrate... Continue Reading


HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

(December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading


FDA Approves Beleodaq for Peripheral T-cell Lymphoma

(July 24, 2014)

The FDA announces its approval of Beleodaq (belinostat), a histone deacetylase inhibitor for treating peripheral T-cell lymphoma (PTCL), based on the results of the BELIEF study that found an overall response rate of nearly 26% among treated patients. PTCL... Continue Reading


More T-Cell Non-Hodgkin's Lymphoma